Current evidence shows that fibrosis is partly mediated by MR pathway (14), and mineralocorticoid receptor antagonists (MRA), as diuretics in treatment of heart failure, is an important potential anti-fibrosis drug. This evidence concerns the gene NR3C2 and heart failure.